dextroamphetamine has been researched along with Glial Cell Tumors in 1 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Excerpt | Relevance | Reference |
---|---|---|
"Fatigue is a common and disabling symptom in people with a primary brain tumour (PBT)." | 2.82 | Interventions for the management of fatigue in adults with a primary brain tumour. ( Bulbeck, H; Cachia, D; Day, J; Rooney, AG; Tremont Lukats, IW; Wefel, J; Yust-Katz, S, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Day, J | 1 |
Yust-Katz, S | 1 |
Cachia, D | 1 |
Wefel, J | 1 |
Tremont Lukats, IW | 1 |
Bulbeck, H | 1 |
Rooney, AG | 1 |
1 review available for dextroamphetamine and Glial Cell Tumors
Article | Year |
---|---|
Interventions for the management of fatigue in adults with a primary brain tumour.
Topics: Adult; Brain Neoplasms; Dextroamphetamine; Fatigue; Glioma; Humans; Modafinil | 2022 |